ptc-logo-orange.png

DMD On-Demand Hub

All the TranslarnaTM (ataluren) webinars in one place. Catch up on the ones you have missed or revisit ones you have enjoyed.

Product-related information is discussed.

DMD Continuum: From early intervention to adult care transition

Join Professor Tracey Willis and Professor Thomas Sejersen as they discuss the disease milestones that define DMD as a continuum, why earlier diagnosis is crucial and the importance of a multidisciplinary approach to improve outcomes.

This is a recording of our live webinar “The DMD Continuum: From early intervention to adult care transition”.

How valuable did you find the content?

Not very valuable
  • 1
  • 2
  • 3
  • 4
  • 5
Very valuable

How valuable did you find the content?

Not very valuable Very valuable
  • 1
  • 2
  • 3
  • 4
  • 5

Safety and effectiveness results of a mutation-specific therapy for DMD in a real-world setting

Professor Mar Tulinius​ reviews the safety and effectiveness of a mutation-specific treatment for nonsense mutation DMD (nmDMD), discussing results from propensity score-matched patient populations from the Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry and the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS).

This is a recording of our live webinar “Individualising DMD: Real-world management of a mutation-specific DMD”.

How valuable did you find the content?

Not very valuable
  • 1
  • 2
  • 3
  • 4
  • 5
Very valuable

How valuable did you find the content?

Not very valuable Very valuable
  • 1
  • 2
  • 3
  • 4
  • 5

Conditional marketing authorisation granted in the European Economic Area is subject to annual reassessment and renewal by the EMA and the European Commission. The European Summary of Product Characteristics for TranslarnaTM (ataluren) is available here. Please refer to your local country guidance for more information.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com.

The website and webinars are organised and funded by PTC Therapeutics, Inc. for healthcare professionals only.

GL-TRNS-0433 | November 2021

The website and webinars are organised and funded by PTC Therapeutics, Inc. for healthcare professionals only. Trademarks, registered or otherwise, are the property of their respective owner(s).

GL-TRNS-0433 | November 2021